Phase I Clinical Trial Using Autologous Ex Vivo Expanded NK Cells and Cytotoxic T Lymphocytes for Cancer Treatment in Vietnam.
| Title: | Phase I Clinical Trial Using Autologous Ex Vivo Expanded NK Cells and Cytotoxic T Lymphocytes for Cancer Treatment in Vietnam. |
|---|---|
| Authors: | Liem NT; Vinmec Research Institute of Stem Cell and Gene Technology, 458 Minh Khai, Hanoi 100000, Vietnam. v.liemnt@vinmec.com.; Van Phong N; Vinmec Research Institute of Stem Cell and Gene Technology, 458 Minh Khai, Hanoi 100000, Vietnam.; Kien NT; Vinmec Research Institute of Stem Cell and Gene Technology, 458 Minh Khai, Hanoi 100000, Vietnam.; Anh BV; Vinmec Research Institute of Stem Cell and Gene Technology, 458 Minh Khai, Hanoi 100000, Vietnam.; Huyen TL; Vinmec Research Institute of Stem Cell and Gene Technology, 458 Minh Khai, Hanoi 100000, Vietnam.; Thao CT; Vinmec Research Institute of Stem Cell and Gene Technology, 458 Minh Khai, Hanoi 100000, Vietnam.; Tu ND; Vinmec Research Institute of Stem Cell and Gene Technology, 458 Minh Khai, Hanoi 100000, Vietnam.; Hiep DT; Vinmec Research Institute of Stem Cell and Gene Technology, 458 Minh Khai, Hanoi 100000, Vietnam.; Hoai Thu DT; Faculty of Biology, VNU University of Science, 334 Nguyen Trai, Hanoi 100000, Vietnam.; Nhung HTM; Vinmec Research Institute of Stem Cell and Gene Technology, 458 Minh Khai, Hanoi 100000, Vietnam. v.nhunghtm@vinmec.com.; Faculty of Biology, VNU University of Science, 334 Nguyen Trai, Hanoi 100000, Vietnam. v.nhunghtm@vinmec.com. |
| Source: | International journal of molecular sciences [Int J Mol Sci] 2019 Jun 28; Vol. 20 (13). Date of Electronic Publication: 2019 Jun 28. |
| Publication Type: | Clinical Trial, Phase I; Journal Article |
| Language: | English |
| Journal Info: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Basel, Switzerland : MDPI, [2000- |
| MeSH Terms: | Colonic Neoplasms/*therapy ; Immunotherapy/*methods ; Killer Cells, Natural/*transplantation ; Liver Neoplasms/*therapy ; Lung Neoplasms/*therapy ; T-Lymphocytes, Cytotoxic/*transplantation; Blood Transfusion, Autologous/methods ; Killer Cells, Natural/immunology ; T-Lymphocytes, Cytotoxic/immunology ; Adult ; Aged ; Aged, 80 and over ; Cells, Cultured ; Female ; Humans ; Male ; Middle Aged |
| Abstract: | (1) Background: Immune cell therapy recently attracted enormous attention among scientists as a cancer treatment, but, so far, it has been poorly studied and applied in Vietnam. The aim of this study was to assess the safety of autologous immune cell therapy for treating lung, liver, and colon cancers-three prevalent cancers in Vietnam. (2) Method: This was an open-label, single-group clinical trial that included 10 patients with confirmed diagnosis of colon, liver, or lung cancer, conducted between March 2016 and December 2017. (3) Results: After 20-21 days of culture, the average number of cytotoxic T lymphocytes (CTLs) increased 488.5-fold and the average cell viability was 96.3%. The average number of natural killer cells (NKs) increased 542.5-fold, with an average viability of 95%. Most patients exhibited improved quality of life, with the majority of patients presenting a score of 1 to 2 in the Eastern Cooperative Oncology Group (ECOG) performance status (ECOG/PS) scale, a decrease in symptoms on fatigue scales, and an increase in the mean survival time to 18.7 months at the end of the study. (4) Conclusion: This method of immune cell expansion met the requirements for clinical applications in cancer treatment and demonstrated the safety of this therapy for the cancer patients in Vietnam. |
| References: | Lancet. 2000 Sep 2;356(9232):802-7. (PMID: 11022927); Nat Immunol. 2002 Jan;3(1):83-90. (PMID: 11743585); Lung Cancer. 2002 Jan;35(1):23-8. (PMID: 11750709); J Exp Med. 2002 Feb 4;195(3):327-33. (PMID: 11828007); J Exp Med. 2002 Feb 4;195(3):335-41. (PMID: 11828008); Immunity. 2003 Oct;19(4):561-9. (PMID: 14563320); J Immunol. 2004 Feb 1;172(3):1333-9. (PMID: 14734707); Nat Immunol. 2004 Dec;5(12):1260-5. (PMID: 15531883); Blood. 2005 Oct 1;106(7):2252-8. (PMID: 15933055); Cancer. 2005 Sep 15;104(6):1129-37. (PMID: 16080176); Anticancer Res. 2005 Nov-Dec;25(6A):3741-6. (PMID: 16302734); Immunity. 2006 Aug;25(2):331-42. (PMID: 16901727); Nat Rev Immunol. 2007 May;7(5):329-39. (PMID: 17438573); Int Rev Immunol. 2008;27(3):93-110. (PMID: 18437601); Cytotherapy. 2008;10(8):775-83. (PMID: 19089686); Stroke Res Treat. 2010;2010:null. (PMID: 20700421); Clin Cancer Res. 2011 Jun 1;17(11):3520-6. (PMID: 21471425); Cell Mol Immunol. 2012 Jan;9(1):45-53. (PMID: 21822297); Nat Rev Immunol. 2011 Aug 26;11(10):645-57. (PMID: 21869816); N Engl J Med. 2011 Sep 22;365(12):1118-27. (PMID: 21992124); Nat Biotechnol. 2011 Oct 13;29(10):867-70. (PMID: 21997622); Cancer Res. 2012 Mar 1;72(5):1081-91. (PMID: 22237626); Cancer Immunol Immunother. 2012 Oct;61(10):1781-90. (PMID: 22422103); CA Cancer J Clin. 2012 Sep-Oct;62(5):309-35. (PMID: 22576456); Case Rep Oncol Med. 2013;2013:903094. (PMID: 23653878); Oncol Lett. 2013 May;5(5):1457-1460. (PMID: 23761810); Oncol Lett. 2013 May;5(5):1611-1614. (PMID: 23761827); J Stem Cells Regen Med. 2011 Oct 30;7(2):95. (PMID: 24693182); J Stem Cells Regen Med. 2012 Nov 26;8(3):205-6. (PMID: 24693200); J Stem Cells Regen Med. 2013 Apr 30;9(1):9-13. (PMID: 24693203); Indian J Hematol Blood Transfus. 2014 Sep;30(Suppl 1):202-4. (PMID: 25332578); CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29. (PMID: 25559415); Onco Targets Ther. 2016 Feb 29;9:1023-8. (PMID: 27013895); World J Hepatol. 2018 Jan 27;10(1):116-123. (PMID: 29399285); Oncol Lett. 2018 Apr;15(4):5730-5738. (PMID: 29552207); J Glob Oncol. 2018 Nov;4:1-9. (PMID: 30422746); N Engl J Med. 1988 Dec 22;319(25):1676-80. (PMID: 3264384); Nature. 1986 Feb 20-26;319(6055):675-8. (PMID: 3951539); Am J Clin Oncol. 1982 Dec;5(6):649-55. (PMID: 7165009) |
| Grant Information: | 001 Vingroup |
| Contributed Indexing: | Keywords: cancer; cytotoxic T lymphocytes; immune cell therapy; natural killer cells; peripheral blood mononuclear cells |
| Entry Date(s): | Date Created: 20190703 Date Completed: 20191206 Latest Revision: 20200225 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC6651639 |
| DOI: | 10.3390/ijms20133166 |
| PMID: | 31261712 |
| Database: | MEDLINE |
Clinical Trial, Phase I; Journal Article